---
document_datetime: 2025-11-27 08:55:30
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.8413333
conversion_datetime: 2025-12-25 07:55:03.444838
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cejemly

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 16/10/2025                          | 21/11/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Cejemly-H-C- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000261157          | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include the treatment of unresectable stage III non - small - cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy for CEJEMLY, based on final results from study CS1001-301; this is a Phase III, multicentre, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of sugemalimab as consolidation therapy versus placebo in participants with locally advanced or unresectable stage III NSCLC who have not progressed after concurrent or sequential chemoradiotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been agreed.   |            |            |             | 6088-II-Var.EMA/VR/0000261157'.   |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUR / EMA/PSUR/0000257890 | - - In view of published PRAC recommendations on signals Coeliac disease and Pancreatic failure associated with immune checkpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 24/07/2025 | 17/09/2025 | SmPC and PL | Variation                         |

<div style=\"page-break-after: always\"></div>

|                                                         | inhibitors, the PRAC concluded that the product information of sugemalimab should be amended accordingly.                                                                                                                                                                                                                                   |            |            |                        |                  |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| Variation type IB / EMA/VR/0000272096                   | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                  | 05/06/2025 | N/A        |                        |                  |
| Article 61(3) /                                         | - Notification acc. Article 61(3) - Accepted Update of the package leaflet to add a list of local representatives. Additionally, the MAH took the opportunity to align the revision date format of the package leaflet with the latest QRD template and to introduce minor editorial amendments to the Slovenian and Czech package leaflet. | 03/04/2025 | 17/09/2025 | PL                     | EMA/N/0000261048 |
| Variation type IA / EMA/VR/0000263406                   | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.a Tightening of in- process limits - Accepted                                                                                                                                                                               | 01/04/2025 | N/A        |                        |                  |
| Marketing Authorisation Transfer - H / EMA/T/0000244822 | - Transfer of a marketing authorisation - transfer of marketing authorisation from SFL Pharmaceuticals Deutschland GmbH to CStone Pharmaceuticals Ireland Limited                                                                                                                                                                           | 04/02/2025 | 10/03/2025 | SmPC, Labelling and PL |                  |